By signing up, you agree to receive recurring automated SMS marketing messages from Mashable Deals at the number provided. Msg and data rates may apply. Up to 2 messages/day. Reply STOP to opt out, HELP for help. Consent is not a condition of purchase. See our Privacy Policy and Terms of Use.
The valuation represents a 31% increase from the $6.1 billion valuation the 13-year-old company achieved in April of last year, when it raised a $575 million round led by Franklin Templeton for partly the same purpose: purchasing shares from employees, including to help them cover the taxes associated with converting expiring restricted stock units (RSUs, a form of equity compensation) into shares.
。新收录的资料对此有专业解读
同时，也有声音好奇，跨国药企做了这么多交易，是否已经填平了一部分专利悬崖、会开始转向避险？专利悬崖确实是跨国药企关注并引入中国创新药管线的重要驱动因素，阿斯利康自身也确有相关考量。但归根结底，它更多是在为企业的布局提供方向指引，最终能解决“焦虑”的是管线够不够重磅（比如出现十亿、百亿美元级别的分子），同时也要正视临床推进可能受阻、需要寻找新替代方案的现实。这都需要时间验证，也意味着跨国药企在创新药BD上的热情和动作不会减弱。。业内人士推荐新收录的资料作为进阶阅读
在创新层面，中国缺乏从0到1的DNA，我们历来擅长学习、继承、发展。而在这个需要大量原创技术驱动的领域，全球Top 20的医疗器械公司中，还没有一家来自中国。我纵览整个产业，觉得这里应该有一个属于中国公司的位置。，这一点在新收录的资料中也有详细论述
В стране ЕС белоруске без ее ведома удалили все детородные органы22:38